Minor histocompatibility antigens (MiHA) play an important role in both graftversus-tumor effects and graft-versus-host disease (GvHD) after allogeneic stem cell transplantation. We applied biochemical techniques and mass spectrometry to identify the peptide recognized by a dominant tumor-reactive donor T-cell reactivity isolated from a patient with relapsed multiple myeloma who underwent transplantation and entered complete remission after donor lymphocyte infusion. A frequently occurring single nucleotide polymorphism in the human ATP-dependent interferon-responsive (
Introduction
Allogeneic stem cell transplantation (SCT) is a curative treatment in patients with hematologic cancers. In addition to the antitumor effects of chemotherapy, antibody treatment and/or irradiation administered as the conditioning regimen prior to transplantation, an allogeneic graft-versus-tumor (GvT) immunereactivity significantly contributes to the curative potential of this therapy. [1] [2] [3] [4] [5] This
GvT reactivity following HLA-matched SCT has been demonstrated to be mediated primarily by T cells from the donor. Allo-reactive T cells from donor origin may not only mediate the beneficial GvT effect but are also responsible for the development of graft-versus-host disease (GvHD), which is the major detrimental complication after allogeneic SCT. 6, 7 T-cell depletion of the stem cell graft removes both GvHD and GvT effect. [8] [9] [10] The antitumor reactivity can be reintroduced in case of persistent or relapsed hematologic malignancies after transplantation by donor lymphocyte infusion (DLI). [11] [12] [13] [14] [15] Whereas profound antitumor effects are frequently associated with GvHD in patients responding to DLI, postponed administration of DLI has been associated with a decreased risk of severe GvHD, and clinical observations indicate that more subtle antitumor reactivities can also be observed in the absence of GvHD. [16] [17] [18] The main targets of both GvHD and GvT reactivity after HLA-matched allogeneic SCT are minor histocompatibility antigens (MiHA). [19] [20] [21] MiHA are peptides differentially expressed by donor and recipient that can be recognized in the context of self-HLA molecules. MiHA may arise from differential processing of peptides due to polymorphisms in the gene encoding the protein or by direct polymorphisms in the peptide sequence that is presented in the HLA molecules. 22, 23 The clinical manifestation of immune responses against MiHA is likely to be determined by the specific tissue expression of the proteins encoding these antigens. Whereas MiHA constitutively expressed in many tissues are likely to be targets for combined alloreactive GvHD and GvT responses, T-cell responses directed against antigens that are restricted to the hematopoietic cell lineages including the malignant cells of hematopoietic origin are likely to mediate a GvT reactivity without severe GvHD. 21, [24] [25] [26] [27] [28] [29] [30] [31] However, antigens with variable expression in tissues may also be targets for relatively specific GvT responses because these proteins may not be expressed or recognized on normal tissues under steady state conditions. 19, 32, 33 By specific stimuli like inflammatory reactions they may be induced in target tissues of GvHD, leading to a detrimental local immune response. 7, 34, 35 Characterization of MiHA from patients responding to cellular immunotherapeutic interventions following allogeneic SCT in the presence or absence of GvHD will lead to a better understanding of the pathogenesis of GvHD and GvT and may lead to the development of specific antitumor T-cell therapy.
Recently, we studied in detail several patients treated for relapsed hematologic malignancies after allogeneic SCT with DLI. During the clinical GvT response,
we isolated tumor-reactive T cells based on their ability to produce IFN-γ in response to specific activation by bone marrow containing the malignant cells. 28, 36 From one of the patients who were treated with DLI for relapsed multiple myeloma (MM) after transplantation with DLI and IFN-α we isolated a dominant cytotoxic T lymphocyte (CTL) clone capable of recognizing the malignant MM cells from the patient. At the time of the clinical response the patient suffered from mild acute GvHD of skin and liver (grade II), which resolved after discontinuation of IFN-α and short-term treatment with prednisone and cyclosporine. The patient entered a complete remission and is now, 6 years later in persistent complete remission without GvHD.
In the present study we identified the MiHA recognized by this CTL clone to be encoded by the ATP-dependent interferon-responsive (ADIR) gene. 37 This gene was found to be highly expressed in the MM cells, in other hematopoietic tumors, as well as non-hematopoietic tumor cell lines. Recognition of normal nonmalignant cells appears to be minor under steady state conditions, but activation of the target cell populations resulted in enhanced recognition by the CTL clone. We hypothesize that T-cell responses against MiHA encoded by the ADIR gene may lead to a strong GvT reactivity, potentially coincident with GvHD depending on the activation state of the target tissues.
Materials and methods

CTL generation and culture
The HLA-A2-restricted MiHA-specific CTL clone RDR2 was previously isolated using the IFN-γ secretion assay from a peripheral blood (PB) sample of a patient at the time of clinical response to DLI as treatment for relapsed MM after SCT. 36 
Cytotoxicity assays
CTL-induced specific cytotoxicity of defined cell types in a heterogeneous target cell population was determined in CFSE-based cellular cytotoxicity assays as described before. 40 Briefly, target cells were labeled with 2.5 μM CFSE (Molecular Probes, Leiden, The Netherlands) and incubated with target cells at 
Sequence analysis of the ADIR gene
Trizol reagent (Invitrogen) was added to patient and donor cell pellets, RNA was isolated and purified, and 4 μg was reverse transcribed into cDNA for 1 hour at 37°C using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen) in accordance with the manufacturer's instructions. Polymerase chain reactions (PCRs) of nucleotides 1 to 327 of the ADIR gene were performed in 50 μL GeneAmpII PCR buffer containing 1.5 mM MgCl 2 , 250 μM dNTPs, 800 nM forward primer (nucleotides 1 to 18), 800 nM reverse primer (nucleotides 309 to 327), 2% DMSO, and 1.5 units of AmpliTaq DNA polymerase. Amplification on an Applied Biosystems GeneAmp PCR system 2400 was achieved in 35 cycles of 15 seconds at 95°C and 30 seconds at 58°C. Sequence reactions were performed on 1 μL of purified PCR product using the Big Dye Terminator v3.1 sequencing kit (Applied Biosystems, Foster City, CA) and 1 μM reverse primer in 25 cycles of 10 seconds at 96°C, 5 seconds at 58°C, and 4 minutes at 60°C. After DNA purification, sequencing was performed using an ABI310 sequencer.
Transfection of constructs containing the LB-ADIR-1F epitope
Constructs from donor and patient cDNA containing the ADIR gene were generated using 3 different forward primers and 1 reverse primer and ligated in pCR3.1 expression vector (Invitrogen) as described previously. 31 A mixture of 100 ng plasmid and 0.8 μL Lipofectamine (Invitrogen) was incubated for 30 minutes at room temperature and used to transiently transfect 2 × 10 4 Hela/A2
cells. After 5 hours of incubation at 37°C, 50 μL IMDM/10% FBS was added.
After 24 hours, 10 4 RDR2 cells were added and again after 24 hours 50 μL of supernatant was harvested and tested for IFN-γ secretion in ELISA.
Ex vivo detection of LB-ADIR-1F specific T cells and T-cell receptor-β variable chain analysis
Recombinant biotinylated HLA-A*02:01 monomers were folded with both ADIR peptide variants. Streptavidin-APC tetramers were produced as described previously. 43 Tetramer-positive events in thawed patient samples were sorted by fluorescence-activated cell sorting (FACS) to single cells per well, expanded, and tested for cytotoxicity as described previously. 21 T-cell receptor-β variable chain (TCRBV) expression of cytotoxic clones and tetramer-positive T cells in patient material was determined by staining with FITC-conjugated mAb to TCRBV7 (Beckman Coulter, Mijdrecht, The Netherlands). Sequences of the TCRBV were determined as described previously, 36 and TCR chains were named in accordance with the nomenclature described by Arden et al.
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Quantitative real-time-PCR to analyze gene expression
Quantitative real-time PCR analysis was performed as described previously. 45 To normalize for variations in the procedures for RNA isolation and cDNA synthesis, 1% mouse spleen cells were added to each cell sample. Quantitative real-time PCR was performed on an ABI/PRISM 7700 Sequence Detector System (Applied Biosystems) using qPCR-Core Kit (Eurogentec, Seraing, Belgium). Human ADIR and PBGD results were normalized using the murine Gapdh expression. For each sample, relative gene expression was calculated using the results obtained from a serial diluted EBV-LCL. EBV-LCL expression was set to 100. Primers for human ADIR were designed spanning exons 1 to 3:
and probe 5′-(TET)-CTGGGCTGGCGCCTTCCTCTGT-(TAMRA)-3′. Primers and probe for human PBGD were as follows:
forward 5′-GCAATGCGGCTGCAA-3′, reverse 5′-GGGTACCCACGCGAATG-3′, and probe 5′-(TET)-CTCATCTTTGGGCTGTTTTCTTCCGCC-(TAMRA)-3′. Primers and probe for murine Gapdh were as follows:
forward 5′-GGGCTCATGACCACAGTCCA-3′
reverse 5′-ATACTTGGCAGGTTTCTCCAGG-3′
and probe 5′-(TET)-TCCTACCCCCAATGTGTCCGTCGT-(TAMRA)-3′.
Results
Isolation of the HLA-A2-restricted CD8 CTL clone RDR2 recognizing a frequently expressed MiHA
We previously described the isolation of various CTL clones from a female patient who was successfully treated with DLI after relapsed MM. 36 CTL clones were generated by direct cloning of IFN-γ-producing cells upon stimulation by irradiated bone marrow cells harvested from the patient prior to SCT. Panel studies using unrelated EBV-LCLs and blocking studies with HLA allele-specific mAb showed that recognition by the most dominant CTL clones was restricted by HLA-A2. Extensive panel studies using PHA blasts and EBV-LCLs of unrelated sibling pairs demonstrated that most HLA-A2-restricted CTL clones designated RDR2 displayed an identical recognition pattern and lysed 57% of targets from all HLA-A2 individuals tested. All RDR2 clones were found to express an identical TCR-BV7S1, N region, and BJ1S4, illustrating that they were derived from the same clonal T cell. 36 Because RDR2 was isolated from a MM patient, we investigated the sensitivity of her MM cells to lysis by the T-cell clone. The CFSE-based cytotoxicity assay was performed to allow quantitative measurement of lysis of MM cells that were present in relatively low frequencies within the heterogeneous bone marrow samples. 40 Figure 1A shows dot plots of a quantitative CFSE-based cytotoxicity assay performed on thawed bone marrow cells from a MiHA-positive patient containing 10% MM cells. Lysis was measured after incubation with a control CMV-pp65-A2-specific CTL clone or with CTL RDR2. CD138 was used as a marker for the malignant MM cells. A strong decrease of the number of CD138 + cells was observed. In a sample containing 1% MM cells that was taken from the patient from which CTL RDR2 was isolated, lysis was measured of bone marrow cells using CD138 as a marker for the malignant MM cells and CD3 as a marker for nonmalignant patient-derived T cells. Figure 1B illustrates that MM cells from the patient were strongly lysed whereas lysis of normal unstimulated T cells was low. Activated T cells (PHA blasts) and EBV-LCLs from the patient were strongly recognized. Donor-derived PHA blasts and EBV-LCLs were not recognized (data not shown). To further study susceptibility of normal hematopoietic cells to lysis by RDR2, PBMC subpopulations from HLA-A2-positive MiHA-positive donors were tested for recognition by RDR2 and an allo-A2 clone. Whereas similar recognition of PHA blasts and EBV-LCLs by the allo-A2 clone and RDR2 was observed, RDR2-mediated lysis of normal B cells and T cells was lower as compared with allo-A2-mediated lysis ( Figure 1C ). In addition, PBMCs were separated by magnetic bead cell sorting into CD4 T cells, CD8 T cells, monocytes, and B cells and were used to stimulate RDR2 and allo-A2 CTL in IFN-γ release assays. Whereas all stimulator cell subpopulations were equally able to induce IFN-γ secretion by allo-A2 CTL, stimulation of RDR2 by normal hematopoietic cells was more than 10-fold lower as compared with stimulation by EBV-LCLs ( Figure 1D ). In conclusion, RDR2 recognized an HLA-A2 restricted epitope causing strong lysis of MM cells and activated T cells and B cells. In contrast, reactivity with normal non-activated hematopoietic cells was relatively low as measured both by direct cytotoxicity and by IFN-γ secretion.
Purification and mass spectrometric identification of the peptide
To identify the epitope that was recognized by CTL clone RDR2, EBV-LCL cells expressing the antigen were lysed, and peptide-HLA complexes were affinity purified using HLA-A2 specific BB7.2 mAb. After elution of peptides, size centrifugation was performed to separate peptides from HLA monomers and β2-microglobulin. After freeze drying, the peptide mixture was subjected to RP HPLC using isopropanol as organic solvent and fractions were collected.
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Crlabeled T2 cells were loaded with a small sample of each fraction. RDR2 was added, and a single positive fraction could be detected. This fraction was subsequently subjected to RP HPLC with acetonitrile as organic solvent and fractionated. Fractions were tested for reactivity, and again a positive fraction was found. To determine the most abundant masses present in this fraction, part of the fraction was injected on a nano-liquid chromatography system directly coupled to a Q-TOF1 mass spectrometer. Abundantly present masses were fragmented by collision-activated dissociation on an HCT plus mass spectrometer. Analysis of obtained fragmentation patterns led to the sequence of several candidate peptides that were subsequently synthesized. RDR2
recognized an [M+2H] ++ candidate peptide with mass/charge of 528.8 and sequence SVAPALALFPA at levels as low as 10 pM (data not shown). Furthermore, the fragmentation patterns of the synthetic peptide and the natural eluted peptide were identical (data not shown). transcript from serine (S) to phenylalanine (F) at position 21, corresponding to position 9 of the eluted peptide (Figure 2A ). Both peptides were synthesized and loaded on T2 cells. Patient-type peptide SVAPALAL-F-PA but not donortype peptide SVAPALAL-S-PA was recognized by RDR2 ( Figure 2B ). Sequence analysis of the ADIR PCR product flanking the SNP revealed that the donor was CC homozygous and the patient CT heterozygous. To demonstrate that patienttype T but not donor-type C of this gene was responsible for recognition by RDR2, constructs were generated from both patient and donor cDNA. Because RDR2 recognized a peptide arising from an alterative ORF controlled by a start codon 5′ upstream from the normal start codon, 3 different forward primers were composed. The first primer was chosen at the normal start codon, thus lacking the alternative start codon. The second primer was chosen at the start of the transcript, thus providing both start codons. The third primer was chosen at the alternative start codon and also contained the normal start codon. The constructs were transiently transfected into Hela/A2 cells. Only patient-derived constructs induced IFN-γ release by RDR2 CTL. Transfection of constructs containing only the normal ORF start codon and lacking the alternative ORF start codon showed a strong decrease of CTL recognition ( Figure 2C ). All donor-derived constructs failed to induce IFN-γ by RDR2 (data not shown).
Identification of a polymorphic gene responsible for RDR2 recognition
Next, a panel of 74 unrelated HLA-A2-positive individuals was analyzed by sequencing for determination of the polymorphism and susceptibility to lysis of PHA blasts by RDR2. A 100% correlation between presence of this specific SNP and CTL reactivity proved that this SNP from C>T in the ADIR gene generates the MiHA epitope SVAPALALFPA that is recognized by RDR2 ( Table  1 ). The MiHA was designated LB-ADIR-1F. 
Tetramer staining and FACS of LB-ADIR-1F-specific CTLs
Both peptide LB-ADIR-1F and peptide SVAPALAL-S-PA were able to bind to recombinant HLA-A*02:01 molecules, and tetrameric complexes were produced. RDR2 specifically bound the LB-ADIR-1F tetramer whereas SVAPALAL-S-PA tetramers and irrelevant HA-1 tetramers were negative (data not shown). LB-ADIR-1F tetramers were used to analyze a series of peripheral blood samples that were taken from the patient before and after DLI. Serum paraprotein levels were analyzed as a marker for disease activity. Whereas LB-ADIR-1F-specific T cells were not detectable prior to DLI, at 7 weeks after DLI high numbers of LB-ADIR-1F-specific CD8 T cells could be detected ( Figure  3A) . PBMCs were incubated for the indicated times in the absence or presence of 1000 IU/mL INF-α or 0.8 μg/mL PHA. Prior to mRNA isolation and cDNA synthesis, 1% mouse spleen cells were added to each sample. Data were normalized to murine Gapdh expression. Expression of EBV-LCLs was set to 100.
Recognition of normal non-hematopoietic cells by LB-ADIR-1F specific CTLs
Recognition of non-hematopoietic normal tissues was studied using BECs and MSCs expressing the LB-ADIR-1F SNP variant in both direct cytotoxicity assays and stimulation assays. Whereas direct cytotoxicity against patient EBV-LCLs was strong, lysis of MSCs ( Figure 5A ) and BECs ( Figure 5B ) was low. LB-ADIR-1F peptide pulsing of MSCs and BECs did not significantly increase lysis, suggesting overall low susceptibility of these target cells to direct cytotoxicity. When MSCs ( Figure 5C ) and BECs ( Figure 5D ) were used as stimulator cells in IFN-γ release assays again, low stimulation by both non-hematopoietic cell types was observed. LB-ADIR-1F peptide pulsing of the stimulator cells increased stimulatory capacity of both MSCs and BECs to levels comparable to stimulation by patient EBV-LCLs. expressing solid tumor lines was tested for recognition by RDR2, lysis at levels comparable to lysis by the allo-A2 CTL was observed ( Figure 6B ). Because the patient was treated with IFN-α and it has previously been described that ADIR gene expression could be up-regulated by interferons, 37 we examined gene expression and LB-ADIR-1F specific recognition of PBMCs that were preincubated with IFN-α. A minor increase in ADIR gene expression was resulting in a complete remission lasting now for more than 6 years.
In conclusion, we characterized a novel MiHA encoded by a frequently occurring SNP in the ADIR gene that is recognized by tumor-reactive CTLs. We hypothesize that the balance between GvT responses and GvHD is not only determined by the specificity of T cells but also by the activation state of GvHD target tissues. [33] [34] [35] 46 Up-regulated tissue susceptibility to MiHA-specific T cells may be caused by the cytokine storm shortly after stem cell transplantation due to conditioning regimens resulting in tissue damage and the presence of high 
